Sesquiterpene lactones isolated from indigenous Middle Eastern plants inhibit tumor promoter-induced transformation of JB6 cells by Melody Saikali et al.
Saikali et al. BMC Complementary and Alternative Medicine 2012, 12:89
http://www.biomedcentral.com/1472-6882/12/89RESEARCH ARTICLE Open AccessSesquiterpene lactones isolated from indigenous
Middle Eastern plants inhibit tumor
promoter-induced transformation of JB6 cells
Melody Saikali1,2,3, Akram Ghantous2,3, Racha Halawi4, Salma N Talhouk3,5, Najat A Saliba3,6
and Nadine Darwiche1,2,3*Abstract
Background: Sesquiterpene lactones (SL) are plant secondary metabolites that are known for their anti-fungal,
anti-bacterial, anti-inflammatory, and anti-tumor properties. Considering that several SL-derived drugs are currently
in cancer clinical trials, we have tested two SL molecules, 3-β-methoxy-iso-seco-tanapartholide (β-tan) isolated from
Achillea falcata and salograviolide A (Sal A) isolated from Centaurea ainetensis, for their anti-tumor properties. We
used the mouse epidermal JB6P + cells as a model for tumor promotion and cellular transformation. Key players that
are involved in cellular transformation and tumorigenesis are the AP-1 and NF-κB transcription factors; therefore, we
assessed how β-tan and Sal A modulate their signaling pathways in JB6P + cells.
Methods: The effects of β-tan and Sal A on the growth of normal and neoplastic keratinocytes and on the tumor
promotion-responsive JB6P + cells were determined using the MTT assay. Anchorage-independent cell growth
transformation assays were used to evaluate the anti-tumor promoting properties of these SL molecules in
JB6P + cells and dual luciferase reporter assays and western blot analysis were used to investigate their effects on
tumor promoter-induced AP-1 and NF-κB activities and protein levels of key AP-1 and NF-кB target genes.
Results: β-tan and Sal A selectively inhibited tumor promoter-induced cell growth and transformation of
JB6P + cells at concentrations that do not affect JB6P + and primary keratinocytes basal cell growth. In addition, both
molecules reduced basal and tumor promoter-induced NF-κB transcriptional activities, differentially regulated basal
and tumor promoter-induced AP-1 transcriptional activities, and modulated key players of the AP-1 and NF-κB
signaling pathways.
Conclusions: These results highlight the anti-tumor promoting properties of β-tan and Sal A. These SL molecules
isolated from two plant species native to the Middle East may provide opportunities for complementary medicine
practices.Background
There is a renewed interest in the use of natural com-
pounds to prevent/treat several types of diseases including
cancer and inflammatory conditions [1,2]. Currently, there
are more than 200 natural product-derived drugs already
in preclinical/clinical development or in the clinic [1,3,4].
The therapeutic properties of medicinal plants are gener-
ally attributed to plant secondary metabolites, an example* Correspondence: nd03@aub.edu.lb
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reproduction in any medium, provided the orof which are sesquiterpene lactones (SL), which are
present almost exclusively in plant species belonging to
the family Asteraceae [5,6]. This family comprises plant
species commonly used in ethnomedicine [7], some of
which have been reported to specifically treat diseases
such as cancer, inflammation, headaches, and infections
[6,8]. Sesquiterpene lactones often colorless and with a bit-
ter taste, are a stable form of terpenoids and are divided
into four groups: germacranolides, eudesmanolides, guaia-
nolides, and pseudoguaianolides [6]. The bioactivity of a
SL molecule has been attributed to several factors includ-
ing the number of alkylating centers, the lipophilicity of
the molecule, and its geometry [9]. Importantly, severaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ical trials [9].
Following bioassay guided fractionation, we have iso-
lated, identified, and characterized two SL molecules of
the guaianolide group, 3-β-methoxy-iso-seco-tanapartho-
lide (β-tan) and salograviolide A (Sal A), with promising
anti-tumor and anti-inflammatory activities [10-14].
β-tan which was purified from Achillea falcata, a spe-
cies native to Lebanon and the Middle East [15], differ-
entially inhibited the growth of the epidermal human
HaCaT cells at non-cytotoxic concentrations to primary
epidermal keratinocytes [11]. Sal A, which was isolated
from Centaurea ainetensis, also a species native to Leba-
non and the Middle East, was found to possess anti-
inflammatory [13,14,16] and anti-cancer activities in a
mouse colon cancer model and in skin cancer cells at
different stages of tumorigenesis [10,12,17].
In this study, we specifically investigated whether these
SL molecules target the tumor promotion stage of tumori-
genesis and cell transformation using the well-established
JB6 mouse epidermal cell system, which includes the
promotion-sensitive P+ cells [18,19]. In contrast to tumor
initiation, tumor promotion is largely reversible,
dependent on epigenetic mechanisms, and is a rate-
limiting step in multi-stage carcinogenesis, making it an
attractive target for anticancer drugs [20,21]. The JB6P+
cells can be transformed to malignancy by tumor promo-
ters, and hence, constitute an ideal model to identify anti-
tumor promoting and chemopreventive agents and to de-
cipher their mechanism of action [19,22-24].
The anti-tumor promoting activities of β-tan and Sal A
and their modulation of AP-1 and NF-κB signaling were
investigated using JB6P+ cells. AP-1 and NF-κB signaling
pathways have been shown to be up regulated and to play
key roles in tumor promotion and epidermal tumorigen-
esis [19,25]. Members of the AP-1 and NF-κB complexes
are expressed at high levels in JB6P+ cells [19], and AP-1
and NF-κB activities are required for tumor promotion
[26,27]. The inhibition of NF-κB and/or AP-1 activities
abrogates transformation in JB6 cells in transgenic mice
and in human keratinocytes [25,28-30].
Methods
Cells and culture conditions
Primary mouse keratinocytes (PMKs) were freshly pre-
pared from one- to-two day-old neonatal BALB-c mice
as described by Yuspa et al. [31]. The SP-1 benign tumor
cell lines were produced in SENCAR mice [31]. The neo-
plastic PAM212 cell line is a differentiated squamous cell
carcinoma (SCC) that spontaneously transformed
in vitro [32]. I7 is a spindle cell line derived from a skin
carcinoma formed from PMKs infected with the v-rasHa
and c-fos oncogenes and grafted to nude mice [32].
PAM212, SP1, and I7 cell lines were generously providedby Dr. Stuart H. Yuspa (NIH, Bethesda, MD). The JB6P +
cell line is a tumor promoter-sensitive clonal variant
(clone 41, subclone 5a), derived from the JB6 model for
tumor promotion, and originally derived from primary
mouse epidermal cells [33]. The JB6P + cell line was gen-
erously provided by Dr. Nancy Colburn (NCI, Frederick,
MD).
SP1, PAM212, and PMK cells were cultured in fresh
Eagle Minimum Essential Medium (EMEM) (Bio Whit-
taker, Cambrex Co., MD) containing 10% chelated fetal
bovine serum (FBS) with no more than 0.05 mM Ca++ to
maintain a basal proliferating cell phenotype [34], 1%L-
glutamine, and 1% penicillin-streptomysin antibiotics
(Gibco-BRL Life Technologies, Carlsbad, CA). I7 cells
were cultured in complete EMEM medium with 10% FBS,
2 mM L-glutamine, and 1% penicillin-streptomysin. JB6P+
cells were cultured in EMEM (SIGMA, M2279) contain-
ing 4% heat inactivated FBS (Gibco BRL Life), 2 mM L-
glutamine, 25μg/mL of gentamicin (SIGMA SG
1397 M10) and 1% non-essential amino acids (NEAA)
(Gibco). JB6P+ cells were used up to ten passages in cul-
ture to avoid spontaneous transformation in vitro. All cells
were grown in a humidified incubator which was set at
95% air and 5% CO2 except for PMKs which were grown
in 93% air and 7% CO2.
Sesquiterpene lactones isolation and cell treatments
Extraction, purification, and identification of the SL β-
tan and Sal A from Achillea falcata and Centaurea aine-
tensis, respectively, were performed as previously
described [11,14]. Briefly, the plant material was soaked in
methanol and then subjected to filtration and several frac-
tionation steps where the different fractions were sub-
jected to bio-guided fractionation. The sub-fractions with
the most potent anti-proliferative activities were further
purified, and the pure bioactive compounds, Sal A from
Centaurea ainetensis and β-tan from Achillea falcata were
identified using 1H and 13C NMR identified using several
spectroscopic techniques including 1D and 2D NMR as
well as mass spectrometry, UV, and IR. β-tan and Sal A
were prepared from a stock of 20 mg/ml diluted in abso-
lute ethanol. Cells were treated with the indicated concen-
trations of β-tan and Sal A. For the control conditions,
concentrations of ethanol in culture medium did not ex-
ceed 0.1% which had no effect on the growth of cells (data
not shown).
Cell growth assay
Cell growth was assayed at indicated time points using the
MTT Cell Proliferation Kit according to manufacturer’s
instructions (Roche Diagnostics). The proliferation assay is
an MTT-based method which measures the ability of
metabolically active cells to convert tetrazolium salt into a
blue formazan product, the absorbance of which is
Saikali et al. BMC Complementary and Alternative Medicine 2012, 12:89 Page 3 of 10
http://www.biomedcentral.com/1472-6882/12/89recorded at 595 nm using an ELISA microplate reader.
Cell growth results were expressed as percentage of con-
trol and were derived from the mean of triplicate wells.
Cells were seeded in 96-well plates, at a density of 1 x 105
cells/ml in 100 μl media, and incubated until confluency
reached 50%. After which the media was removed and
100 μl of fresh media containing different concentra-
tions of β-tan or Sal A were placed for treatment
conditions, or a maximum of 0.1% ethanol in media
for control conditions. For MTT assays using the
phorbol ester 12-O-tetradecanoylphorbol-13-acetate
(TPA) (Enzo Life Sciences, USA), JB6P + cells were
treated with either 5 nM TPA [35] in media only, or
with the indicated concentrations of β-tan or Sal A
with or without 5 nM TPA co-treatment.
Anchorage-independent growth transformation assay
Colony growth in soft agar is a well-established index of
cell transformation [24]. Anchorage-independent growth
was studied using the CytoSelectTM 96-Well Cell Trans-
formation Assay kit (Cell Biolabs) according to manufac-
turer’s instructions. The base agar layer (0.6% agar, 10%
FBS, 2 mM L-glutamine and 25 μg/ml gentamicin) was
layered into wells of a 96-well plate and allowed to solid-
ify. Once solidified, the cell agar layer containing 0.4%
agar with JB6P+ cells treated with the indicated concen-
trations of β-tan and Sal A, with 5 nM TPA [23,35,36],
in complete EMEM (10% FBS), was layered on top of the
base agar layer. The indicated concentrations of β-tan and
Sal A were then prepared in complete EMEM (10% FBS),
with 5 nM TPA and placed over the solidified cell agar
layer. The cells were incubated for 9 ± 1 day at 37°C and
5% CO2, replenished with the indicated concentrations of
β-tan and Sal A with 5 nM TPA every 3 days. Colonies
were photographed and then quantified using the
CyQuant GR Dye where the fluorescence was measured
using a 96-well fluorometer set at a 485/520 nm filter set.
Dual luciferase reporter assay for AP-1 and NF-κB
transcriptional activities
JB6P + cells were seeded in 24-well plates (1 x 105 cells/
ml), and at 60–80% confluency, cells were co-transfected
with the AP-1 (pXP2-35alb-Luc, 0.8 μg) or NF-κB
(pGL2-IL-6–Luc, 0.8 μg) firefly luciferase reporter plas-
mids with the renilla luciferase reporter plasmid (pRL-
SV40, 0.04 μg). The pXP2-35alb-Luc harbors the albu-
min promoter upstream from the luciferase gene. Within
this promoter, the GCN4 oligo sequence, which harbors
the AP-1 binding site, was ligated. The pGL2-IL-6–Luc
uses the IL-6 promoter region containing four putative
NF-κB binding sites. These reporter plasmids were
kindly provided by Dr. Nancy Colburn (NCI). Co-
transfection was done using LipofectamineTM 2000 with
PLUSTM reagent (Invitrogen), without antibiotics for 3 hat 37°C, 5% CO2, then replenished with complete EMEM
(4% heat-inactivated FBS, with antibiotics) for at least
12 h. Cells were then treated with the indicated concentra-
tions of β-tan and Sal A, with or without 16 nM TPA for
24 h as described [35]. Cell lysates were then prepared and
luminescence measured using the Dual Luciferase Re-
porter Assay Kit (Promega) as per manufacturer’s instruc-
tions. The firefly reporter transfection efficiencies were
normalized relative to the renilla luciferase activity gener-
ated by this vector and plotted as percentage of control.
Western blot analysis
JB6P + cells were plated in 100 mm dishes at a density of
50,000 cells/ml. At 80–90% confluency, cells were
starved with 0.1% FBS for 24 h, then were pre-treated
with either 10 μg/ml β-tan or 15 μg/ml Sal A for 1 hr
followed by 15 min or 6 h 32 nM TPA [35,37]. Whole
cell protein extracts (30 μg) were prepared as described
[10] and probed overnight at +4 °C with primary anti-
bodies against MMP-9 (Chemicon, Millipore) MMP-2
(Chemicon, Millipore), GAPDH, IκBα, cyclin D1, p16,
Bax and Bcl-2 (Santa Cruz Biotechnology, Inc.) followed
by secondary antibodies conjugated with horseradish
peroxidase. Equal protein loading and quality were veri-
fied through GAPDH reprobing and Ponceau staining of
membranes. The immunocomplexes were visualized
using enhanced chemiluminescent kits obtained from
Santa Cruz (ECL system). Bands were quantified using
ImageQuant software and the Molecular Dynamics 860
System (Molecular Dynamics, Sunnyvale, CA). In some
western blots, adjustments of brightness and contrast
were applied to all bands of the same membrane image.
Statistical analysis
Data presented are the means±SE of at least two independ-
ent experiments or as indicated. Significant differences were
determined using the post-hoc tests; Tukey, SNK and Dun-
nett tests of the SPSS Version 16.0 software. Significance
was set at indicated p-values (0.05, 0.01 or 0.001).
Results
We have previously shown that β-tan and Sal A which
belong to the same guaianolide group, exhibit selective
anti-tumor activities with minimal effects on normal
cells [11,17]. In this study, we investigated whether Sal A
and β-tan (Figure 1), attenuate tumor promotion, using
the JB6 tumor model. We focused on AP-1 and NF-κB
signaling pathways, known to play crucial roles in tumor
promotion and in epidermal carcinogenesis [19].
β-tan and Sal A selectively inhibit the growth of tumor
cells
We have previously shown, in a murine in vitro model of
epidermal carcinogenesis, that Sal A selectively inhibits
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Figure 1 Chemical structures of 3-β-methoxy-iso-seco-tanapartholide (β-tan) and salograviolide A (Sal A) from Achillea falcata and
Centaurea ainetensis, respectively.
A
B
Figure 2 β-tan and Sal A selectively inhibit the growth of JB6P+
cells. At 50–60% confluency, primary mouse keratinocytes (PMK), SP-
1, PAM212, I7 (A) and JB6 P+ (B) cells were treated with the
indicated β-tan or Sal A concentrations, or 0.1% ethanol as the
control. Cell growth was determined at 24 h and expressed as
percentage of control (Ct) treated cells using the MTT Cell
Proliferation Kit, as described in Materials and Methods. Significance
between neoplastic cell lines and PMKs is indicated by * at p< 0.05
or ** at p< 0.01. Results represent the mean (± SEM) of at least two
independent experiments done in triplicate wells.
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significantly affecting the growth of normal cells [10].
Here, we characterized the growth-inhibitory effects of β-
tan in vitro using an MTT-based assay. In this model, the
primary mouse keratinocytes (PMKs) are representatives
of normal cells, the SP-1 cell line as benign tumor cells,
PAM-212 cell line as SCC, and the spindle I7 cells as ag-
gressive and metastasizing tumor cells. Treatment with β-
tan caused a dose-dependent growth inhibition at 24 h,
where a concentration of 10 μg/ml decreased cell growth
significantly by 49 ±7% (p< 0.01) in PAM 212 cells com-
pared to a 6± 1% decrease in PMKs cell growth
(Figure 2A). The benign SP-1 cells and spindle I7 cells
appeared to be less sensitive at this concentration, showing
a 26± 10% and 30± 4% decrease, respectively, that were
not significantly different than the normal PMKs
(Figure 2A). We have previously performed similar experi-
ments on Sal A and found that 10 μg/ml is selective for
tumor cells [10]. In this study, we used this same concen-
tration (10 μg/ml) to study the effect of both β-tan and Sal
A on JB6P+ cell growth and transformation. β-tan and Sal
A produced a dose-dependent growth inhibition in JB6P+
cells (Figure 2B). Treatment with 10 μg/ml β-tan and Sal
A inhibited JB6P+ cell growth by a significant 74± 7% and
51±4% (p< 0.01), respectively (Figure 2B). These results
show that at low concentrations, both molecules preferen-
tially inhibited the growth of JB6P+ cells versus normal
keratinocytes, eliminating the possibility that the anti-
tumor promoting effects of β-tan and Sal A is due to drug
cytotoxicity.
β-tan and Sal A inhibit tumor promoter-induced
proliferation and transformation of JB6P+ cells
We investigated the anti-tumor promoting properties of
β-tan and Sal A in JB6P + cells. Tumor promoters, such
as the phorbol ester 12-O-tetradecanoylphorbol-13-
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formation. Treatment of JB6P + cells with TPA alone sig-
nificantly increased their growth at 48 h by
approximately 160 ± 7% relative to control (p< 0.001)
(Figure 3A). However, co-treatment with β-tan or Sal A
with TPA for 48 h inhibited tumor promoter-induced
proliferation of JB6P + cells (Figure 3A). β-tan treatment
for 48 h at 1 or 2.5 μg/ml did not cause a significant
growth inhibition of JB6P + cell proliferation compared
to control treated cells (p> 0.05) (Figure 3A). However,
co-treatment of 2.5 μg/ml β-tan with TPA showed a sig-
nificant (p< 0.001) inhibition of TPA-induced prolifera-
tion, by 28 ± 10%, relative to the TPA-treated cells;
whereas, co-treatment of 1 μg/ml β-tan with TPAA
B C
Figure 3 β-tan and Sal A inhibit promoter-induced proliferation and t
were treated with the indicated concentrations of β-tan and Sal A, with or
and expressed as percentage of control (Ct) treated cells using the MTT Ce
at p< 0.001 while significance from control treatment is indicated by *** at
independent experiments done in triplicate wells. (B, C) In the anchorage-i
agar over 0.6% base agar layers, with the indicated β-tan and Sal A concen
every three days, where the co-treatment of 2.5 μg/ml β-tan or Sal A with
and quantified at 9 ± 1 day post-seeding using the CytoSelectTM Transforma
treated cells and plotted as mean colony growth (± SEM) of two independ
control is indicated by ††† at p< 0.001.showed no significant inhibition on TPA-induced prolif-
eration (p> 0.05) (Figure 3A). β-tan concentrations of 5
and 10 μg/ml had a significant growth inhibitory effect
after 48 h on JB6P+ cells (by 70 ± 3% and 80 ± 3% re-
spectively) relative to control (p< 0.001), and when co-
treated with TPA, cell proliferation was significantly
decreased (p< 0.001) (Figure 3A).
Treatment with Sal A at 5 μg/ml had no growth inhibi-
tory effect in JB6P + cells while this concentration caused
a significant inhibition of TPA-induced proliferation by
33 ± 20% relative to the TPA-treated cells (p< 0.001)
(Figure 3A). Higher concentrations of Sal A at 10 or
15 μg/ml caused a significant 63 ± 3% and 65 ± 1% de-
crease in cell proliferation, respectively, with or withoutransformation of JB6P+ cells. At 50–60% confluency, JB6P+ cells
without TPA co-treatment. (A) Cell growth was determined at 48 h
ll Proliferation Kit. Significance from TPA treatment is indicated by †††
p< 0.001. Results represent the averages (± SEM) of at least two
ndependent growth assay, JB6P+ cells were suspended in 0.4% soft
trations (μg/ml) and TPA co-treatment. Treatments were replenished
TPA and colony growth was photographed at 200X magnification (B)
tion Assay (C). Colony growth is expressed as percentage of TPA only-
ent experiments done in triplicate wells (C). Significance from TPA
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indicate that both SL molecules reduced tumor promoter-
induced proliferation of JB6P+cells at concentrations that
did not affect the growth of normal cells.
To test whether these two SL molecules inhibit tumor
promoter-induced cell transformation, we determined
their effects on anchorage-independent cell growth in soft
agar, which is a hallmark of malignant transformation. In
the presence of tumor promoters, the immortalized but
non-tumorigenic JB6P+ cells become tumorigenic, form-
ing colonies in an anchorage-independent manner [23].
JB6P+ cells treated with only TPA, but not solvent control,
exhibit colony growth in soft agar (Figure 3B, C).
Importantly, upon co-treatment of β-tan or Sal A with
TPA, colony formation was inhibited in a concentration-
dependent manner in JB6P+ cells (Figure 3B, C). At
0.25 μg/ml, neither β-tan nor Sal A decreased JB6P+ col-
ony growth 9±1 day after seeding; however, at 2.5 μg/ml
concentrations, which were non-cytotoxic to normal and
JB6P+ cells by MTT (Figure 2), β-tan and Sal A signifi-
cantly inhibited tumor promoter-induced colony forma-
tion by 66± 8% and 51±8%, respectively (p< 0.001)
(Figure 3B, C). Both SL molecules completely abrogated
colony growth 9± 1 day post-seeding at 5 μg/ml concen-
trations. These results show that β-tan and Sal A inhibit
tumor promoter-induced JB6P+ cell transformation.
β-tan and Sal A differentially modulate TPA-induced NF-
κB and AP-1 activities in JB6P+ cells
Elevated levels of AP-1 and NF-κB activities are hall-
marks of malignant transformation [19,27,37]. Since β-tan
and Sal A both inhibited tumor promoter-induced cell
transformation, we hypothesized that these SL molecules
mediate their anti-tumor promoting activities by repres-
sing AP-1, NF-κB, or both transcriptional activities.
The application of TPA alone dramatically increased
AP-1 and NF-κB luciferase activities in JB6P + cells by
four- and approximately two-fold, respectively, compared
to control (Figure 4). We tested the effects of β-tan and
Sal A on TPA-induced AP-1 and NF-κB transcriptional
activities for 24 hours, using 5 μg/ml concentrations as
these completely abrogated colony formation with min-
imal effects on primary keratinocyte cell growth. Unex-
pectedly, at this concentration, β-tan showed a
significant 2.5-fold increase in basal AP-1 activity, rela-
tive to control (p< 0.01) and did not decrease TPA-
induced AP-1 activity (Figure 4A). Importantly, 5 μg/ml
β-tan showed a significant inhibition of basal and TPA-
induced NF-κB activity by 50 ± 4% and 64 ± 4%, respect-
ively, at 24 h (p< 0.001) (Figure 4A).
Sal A (5 μg/ml) did not modulate basal AP-1 activity,
but caused a non-statistically significant decrease in TPA-
induced AP-1 activity. Interestingly, Sal A significantly
decreased basal and TPA-induced NF-κB transcriptionalactivities at 24 h by 37 ± 6% and 54 ± 5%, respectively
(p< 0.01) (Figure 4B). Our experiments show that both
β-tan and Sal A decreased basal and tumor promoter-
induced NF-κB activities, which in fact is a characteristic
property of SL [6].
β-tan and Sal A modulate key target genes of the AP-1
and NF-κB signaling pathways in JB6P+ cells
In JB6 cells, both AP-1 and NF-κB activities are essential
for the transformation response, which can be attributed
to their roles in the transcriptional activation of genes
controlling cellular proliferation, metastasis, angiogen-
esis, tumor invasion, and apoptosis [38,39]. We next
investigated the effect of β-tan and Sal A on the protein
levels of key downstream targets of the AP-1 and NF-κB
pathways known to be induced by tumor promoters in
cell transformation and tumor progression. These target
genes are modulated by tumor promoters at early time
points; therefore, we pretreated JB6P + cells for one hour
with high concentrations of β-tan (10 μg/ml) and Sal A
(15 μg/ml), followed by TPA for 15 minutes or 6 hours.
We chose these high concentrations that kill approxi-
mately 70% of cells by 24 h to be able to detect early
protein changes of key AP-1 and NF-κB target genes.
Protein levels of metalloproteinase 9 (MMP-9) were
induced by approximately 11-fold in TPA-treated JB6P+
cells as early as 15 minutes and were reduced to basal
levels and by approximately 50% by pre-treatment with
β-tan and Sal A, respectively (Figure 5). On the other
hand, MMP-2 protein levels were induced by three-fold
in TPA-treated JB6P + cells at 15 minutes but were not
reduced by β-tan or Sal A pretreatment. As early as 15
minutes post-TPA treatment, cyclin D1 protein levels
were increased by four-fold, and were slightly decreased
upon pretreatment with β-tan (Figure 5). The cyclin-
dependent kinase inhibitor (CDKI) p16 was reduced by
TPA at 15 minutes and 6 hours, and pretreatment with
β-tan or Sal A increased p16 protein levels to control or
higher levels by 6 hours (Figure 5). Furthermore, we
investigated the changes in pro-apoptotic Bax and anti-
apoptotic Bcl-2 proteins upon treatment with β-tan or
Sal A in the presence of TPA. These apoptotic regulators
are also key target genes for mediating the AP-1 and NF-
κB transformation response. An increase in the ratio of
pro-apoptotic over anti-apoptotic Bcl-2 proteins leads to
an increase in mitochondrial permeability and subse-
quent release of cytochrome c, an event central to apop-
totic activation [40]. Treatment with TPA alone reduced
the pro-apoptotic Bax/Bcl-2 protein ratio to 0.3 folds of
control as early as 15 minutes (Figure 5). Pre-treatment
with β-tan or Sal A restored the Bax/Bcl-2 protein ratio
to almost control values at 15 minutes and to more than
two- and four-fold of control values at 6 hours post-TPA
treatment (Figure 5).
AB
Figure 4 β-tan and Sal A decrease basal and TPA-induced NF-κB transcriptional activities. At 60–80% confluency, JB6P+ cells were
transiently co-transfected with control renilla luciferase reporter construct and AP-1 or NF-κB firefly luciferase reporter constructs and were
pre-treated with the indicated concentrations of β-tan (A) or Sal A (B) for 1 h followed by TPA treatment up to 24 h. Results were standardized
relative to renilla luciferase and expressed as percentage of control (Ct)-treated cells. Significance from Ct-treated condition is indicated as ** at
p< 0.01 and *** at p< 0.001. Significance from TPA-control condition is indicated as †† at p< 0.01 and ††† at p< 0.001. Results are representative
of two independent experiments and plotted as averages of triplicate wells (± SD).
Figure 5 β-tan and Sal A modulate the protein levels of key AP-1 and NF-κB downstream target genes in JB6P+ cells. JB6P + cells were
plated in 100 mm dishes at a density of 50,000 cells/ml. At 80–90% confluency, cells were starved with 0.1% FBS for 24 h, then were pre-treated
with either 10 μg/ml β-tan or 15 μg/ml Sal A for 1 h, followed by 15 min or 6 h TPA treatment. Whole cell proteins were immunoblotted with
the indicated antibodies and reprobed with GAPDH antibody to ensure equal protein loading. Densitometry values were standardized relative to
GAPDH for each condition and results are expressed relative to control (Ct) treated cells for each time point. Densitometry values for Bax:Bcl-2
protein ratios are indicated in italics.
Saikali et al. BMC Complementary and Alternative Medicine 2012, 12:89 Page 7 of 10
http://www.biomedcentral.com/1472-6882/12/89
Saikali et al. BMC Complementary and Alternative Medicine 2012, 12:89 Page 8 of 10
http://www.biomedcentral.com/1472-6882/12/89Since both SL molecules inhibited TPA-induced NF-
κB transactivation, we next studied their effects on the
NF-κB inhibitor, IκBα. Treatment with TPA alone abro-
gated IκBα protein levels as early as 15 minutes (Fig-
ure 5). Interestingly, only pre-treatment with β-tan
restored IκBα protein levels after 15 minutes of TPA-
treatment. These results indicate that pretreatment with
β-tan or Sal A regulate TPA-induced AP-1 and NF-кB
target genes that are involved in the regulation of cell
growth, cell migration, and metastasis.
Discussion
In this study, we investigated the anti-tumor promoting
effects of β-tan and Sal A, isolated from Achillea falcata
and Centaurea ainetensis, respectively, using the JB6 epi-
dermal cell model of tumor promotion and cell transform-
ation. In the multi-stage model of carcinogenesis, the tumor
promotion phase is a rate limiting step that is responsible
for the clonal expansion of initiated cells and is largely re-
versible [41], offering a practical approach for identifying
potential inhibitors of cancer development [42].
Herein, we report that treatment with either Sal A or
β-tan preferentially inhibited the growth of murine neo-
plastic keratinocytes, whilst sparing normal cells. The
promotion-sensitive JB6P + cells were the most sensitive
to β-tan treatment at concentrations that did not affect
the growth of PMKs. Treatment with Sal A was relatively
less potent on JB6P + cells, compared to β-tan, where
10 μg/ml β-tan inhibited cell growth by 74 ± 7%, whereas
10 μg/ml Sal A inhibited by 51 ± 4%. Although both be-
long to the SL guaianolide family, it seems that β-tan,
with its relatively open ring structure, possesses higher
flexibility, possibly enhancing β-tan diffusion across the
cell membrane; in contrast to Sal A which bears a closed
ring structure (Figure 1). In addition to the bioactive –α-
methylene-γ-lactone ring present in Sal A and β-tan, the
latter harbors an additional alkylating center, the cyclo-
pentenone. Moreover, the presence of two hydroxyl
(OH) groups within Sal A renders the molecule less lipo-
philic, possibly decreasing cell membrane penetration
and may explain its reduced toxicity to JB6P + cells com-
pared to β-tan.
In studying the anti-tumor promoting properties of
these two purified SL molecules, it was essential to assess
their effect on TPA-induced JB6P + cell transformation.
In this study, we found that both β-tan and Sal A inhib-
ited TPA-induced JB6P + cell transformation, at concen-
trations not cytotoxic to normal nor to the non-
tumorigenic JB6P + cells. A hallmark of cell transform-
ation is the ability of malignant cells to grow in soft agar
in an anchorage-independent manner [18,23,36]. Our
results show that β-tan and Sal A, at concentrations that
did not inhibit JB6P+ cell proliferation, were effective in
reducing TPA-induced proliferation and inhibiting TPA-induced colony formation. These results suggest that β-
tan and Sal A may have promising chemopreventive
properties in epidermal carcinogenesis. Future in vivo
experiments are required to confirm the chemopreven-
tive properties of these purified SL molecules. However,
a limiting step for in vivo studies will be the availability
of large quantities of these molecules.
The activation of the transcription factors AP-1 and
NF-κB is essential for tumor promotion and neoplastic
transformation, and are highly expressed in the
promoter-sensitive JB6P + cells, and the inhibition of both
or either one of these signaling pathways is sufficient to
inhibit neoplastic transformation [19,23,25]. To study the
modulation of tumor promoter-induced AP-1 and NF-κB
transcriptional activities by β-tan and Sal A in JB6P+
cells, concentrations that inhibited JB6P + cell transform-
ation and did not affect normal cell growth were used.
Interestingly, both SL molecules decreased basal and
TPA-induced NF-κB activities, but not of TPA-induced
AP-1 activity. This suggests that β-tan and Sal A primar-
ily inhibit NF-κB signaling in tumor cells. In fact, it is well
established that NF-κB is a vital molecular target for vari-
ous SL, and some of them, such as parthenolide, artimisi-
nin and thapsigargin are currently in cancer clinical trials
[6,9,43]. This can be attributed to the presence of the α-
methylene-γ-lactone functional group, which directly
alkylates cysteine residues of the p65 subunit, interfering
with DNA binding [6,44]. In fact, elevated NF-κB signal-
ing is sufficient to induce epidermal tumor transform-
ation [27]. This prompted us to study the effect of these
SL molecules on the protein levels of one of the main
NF-κB inhibitors, IκBα. Previous studies have shown that
the expression of non-degradable mutants of IκBα and
antisense RNA inhibition of NF-κB, result in tumor re-
gression [29,45-47]. Interestingly, only pre-treatment
with β-tan restored IκBα protein levels after 15 minutes
of TPA-treatment, suggesting that Sal A and β-tan differ-
entially mediate their inhibition of NF-κB signaling. This
differential regulation of IκBα proteins by the SL mole-
cules can be attributed to their differences in alkylating
centers and lipophilicity, thus, affecting their interaction
with the IκBα proteins. Nevertheless, β-tan also signifi-
cantly increased basal AP-1 levels in JB6P + cells at con-
centrations that decreased cell growth. This may
implicate the dual role of AP-1 in increased cell prolifera-
tion and cell death [48].
Since earlier studies have shown that AP-1 and NF-κB
can interact together [49], we assessed how both SL
molecules modulated key downstream target genes, con-
taining TPA response elements (TREs) common to both
AP-1 and NF-κB. Metalloproteinases are essential for
tumor promotion, progression, and invasion and AP-1
and NF-κB play a dominant role in the transcriptional
activation of the majority of MMPs [50,51] including
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ing MMP-9 that this gene is functionally involved in the
regulation of oncogene-induced keratinocyte hyperproli-
feration, progression to invasive cancer, and end-stage
malignant grade epithelial carcinomas [52]. Treatment of
TPA-promoted JB6P + cells with β-tan or Sal A, abro-
gated MMP-9, but not MMP-2, protein levels. This im-
plies that the two SL molecules differentially modulate
MMP protein levels suggesting the regulation of MMP2
by factors other than AP-1 and NF-κB.
Another important AP-1 and NF-κB target gene is the
CDKI p16. Both SL molecules noticeably up regulated
p16 that was reduced upon TPA treatment, which sug-
gests that β-tan and Sal A inhibit cell cycle progression
that is induced by tumor promoters. Furthermore, AP-1
and NF-κB components also regulate apoptotic proteins
such as the pro-apoptotic Bax and the anti-apoptotic
Bcl-2 proteins [38,51]. SL are known to be inducers of
apoptosis in a variety of cancer cells, and this is consid-
ered one of the important mechanisms by which SL
exert their anti-tumor properties [6]. Our results show
that both β-tan and Sal A increase the Bax:Bcl-2 ratios
in TPA-promoted JB6P + cells and suggest that Bcl-2
family members are involved in the growth suppressive
effects of β-tan and Sal A.Conclusions
This is the first report which investigates the anti-tumor
promoting effects of the SL β-tan and Sal A in cell trans-
formation. Our studies highlight the mechanism by
which these SL molecules inhibit tumor promotion by
reducing TPA-induced NF-κB activity and in regulating
several downstream players involved in cell cycle pro-
gression, apoptosis, and tumor invasion. It is well estab-
lished that tumor promotion is epigenetically regulated,
and numerous plant-derived anti-cancer drugs are mod-
ulators of epigenetic processes [53], therefore it would be
interesting to test whether these purified SL molecules
are epigenetic regulators. Finally, future studies investi-
gating the anti-tumor promoting properties in vivo are
needed to test the potential chemopreventive use of
these SL molecules.
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